2 completed, 1 terminated. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 2, Terminated 1 |
Follow Ultibro: new trials by email Literature Review of Ultibro trials Research Report on Ultibro
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ANTES B+ Clinical Trial Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Brimica, Duaklir - Chronic Obstructive Pulmonary Disease | Phase 4 | Terminated | Fundacio Privada Mon Clinic Barcelona | 48 | 2024-02-29 | 2025-08-14 |
| Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD indacaterol/glycopyrronium 110/50 Breezhaler®, Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation - COPD | Phase 4 | Completed | Wouter H. van Geffen | 40 | 2015-12-01 | 2017-10-11 |
| Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients QVA149, Placebo - Chronic Obstructive Pulmonary Disease, COPD | Phase 4 | Completed | Novartis Pharmaceuticals | 62 | 2015-05-18 | 2019-01-03 |
Pulmonary Disease, Chronic Obstructive (3) · Dyspnea (1)
Fundacio Privada Mon Clinic Barcelona (1) · Novartis Pharmaceuticals (1) · Wouter H. van Geffen (1)
Germany (1) · Netherlands (1) · Spain (1)
Huib AM Kerstjens, prof. dr. (1) · Wouter H van Geffen, MD (1)
2014 (1), 2023 (1)